Neuroprotectant drugs in cisplatin neurotoxicity

Anticancer Research

Volumn 16, Issue 5 B, 1996, Pages 3149-3159

  Cavaletti, Guido ^a,d   Cascinu, Stefano ^b   Venturino, Paola ^c   Tedeschi, Michele ^c   Tredici, Giovanni ^d  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Boehringer Ingelheim Italia SpA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Cisplatin; Clinical studies; Neuroprotective agents; Neurotoxicity; Preclinical studies

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CALCIUM ANTAGONIST; CISPLATIN; CORTICOTROPIN DERIVATIVE; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; THIOL DERIVATIVE;

ARTICLE; CANCER SURVIVAL; NEUROPROTECTION; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CISPLATIN; CLINICAL TRIALS; HUMANS; NERVE GROWTH FACTORS; NERVE TISSUE PROTEINS; NERVOUS SYSTEM; SULFHYDRYL COMPOUNDS;

EID: 0029801241     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8: 1777-1781, 1990.
2. Neijt JP: Treatment of advanced ovarian cancer: 10 years of experience. Ann Oncol 3: 17-27, 1992.
3. Al-Sarraf M: Head and neck cancer: chemotherapy concepts. Semin Oncol 1: 70-85, 1988.
4. Bunn PA: The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 16: 10-21, 1989.
5. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig MY, Young RC, Muggia FM: Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat Rep 63: 1527-1531, 1979.
6. Fisher DS, Kobf MF, Durivage HJ The cancer chemotherapy handbook. Mosby-Handbook, St Louis, MO 4th ed, 1993.
7. Bozzino JM, Prasad V, Koriech OM: Avoidance of renal toxicity by 24 hour infusion of cisplatin. Cancer Treat Rep 65: 351-352, 1981.
8. Weis RB, Poster DS: The renal toxicity of cancer chemotherapeutic agents. Cancer Treat Rev 9: 37-56, 1982.
9. Ozols RF, Corden BJ, J, Wesley MN, Dstellega Y, Young RC: High-dose cisplatin in hypertonic saline. Ann Intern Med 100: 19-24, 1984.
10. Levin L, Hyrniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5: 756-767, 1987.
11. Ozols RF, Thigpen JT, Colombo N, Piccart MJ, Bertelsen K, Levin L, Lund B: Dose intensity. Ann Oncol 4: 49-56, 1993.
12. Hamers FTP, Gispen WH, Neijt JP: Neurotoxic side-effects of cisplatin. Eur J Cancer 3: 372-376, 1991.
13. Cersosimo RJ: Cisplatin neurotoxicity. Cancer Treat Rev 16: 195-211, 1989.
14. Thompson SW, Davis LE, Kornfeld M, Hilgers Rd, Standefer JC: Cisplatin neuropathy: clinical, electrophysiologic, morphologic and toxicologic studies. Cancer 7: 1269-1275, 1984.
15. Clark AW, Parhad IM, Griffin JW, Price DL: Neurotoxicity of cisplatinum: pathology of the central and peripheral nervous system. Neurol 30: 429, 1980.
16. Tomiwa K, Nolan C, Cavanagh JB: The effects of cisplatin on rat spinal ganglia: a study by light, electron microscopy and by morphometry. Acta Neuropathol 69: 295-308, 1986.
17. 4-9 on neural transport in cisplatin induced neurotoxicity. Brain Res 676: 258-267, 1995.
18. Rebert CS, Pryor GT, Frick MS: Effects of vincristine, maytansine and cisplatinum on behavioral and electrophisiological indices of neurotoxicit,v in rats. J Appl Toxicol 4: 330-338, 1984.
19. De Koning P, Nejit, Jennenkens FGI, Gispen WH: Evaluation of cis-diaminedichloroplatinum (II) (cisplatin) neurotoxicity in rats: Toxicol Appl Pharmacol 87: 81-87, 1987.
20. Haggerty GC: Development of Tier I neurobehavioral testing capabilities for incorporation into pivotal rodent safety assessment studies. J Amer Coll Toxicol 8: 53-70, 1989.
21. Goldberg JM, Lindblom U: Standardised method of determining vibratory perception threshold for diagnosis and screening in neurological investigation. J Neurol Neurosurg Psych 42: 793-803, 1979.
22. Roelofs RJ, Hrushesky W, Rogin J, Rosenberg L: Peripheral sensory neuropathy and cisplatin chemotherapy. Neurol 34: 934-938, 1984.
23. Daugaard GK, Petrera J, Trojaborg W: Electrophysiological study of the peripheral and central neurotoxic effect of cisplatin. Acta Neurol Scand 76: 86-93, 1987.
24. Boogerd W, ten Bokkel Huinink WW, Dalesio O, Hoppenbrouwers WJJF, Van der Sande J: Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. Neuro-Oncol 9: 255-263, 1990.
25. Gregg RW, Molepo JM, Monpetit VJA, Mikael NZ, Redmond D, Gadia M, Stewart DJ: Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 5: 795-803, 1992.
26. Haragsim L, Zima T: Protective effects of verapamil on cis-platinum and carboplatinum nephrotoxicity in dehydrated and normohydrated rats. Biochem Int 28: 273-276, 1992.
27. Garcia Cosmes P, Mortezo A, Lopez Novoa JM, Marcias Nunez JF: Is renal protection with calcium antagonists possible? Drugs 44: 99-102, 1992.
28. Uozumi J, Ueda T, Yasumasu T, Koikawa J, Kumazawa J: Calcium blockers enhance cisplatin-induced nephrotoxicity in rats. Int Urol Nephrol 24: 549-553, 1992.
29. Hamers FPT, Gerritsen Van der Hoop R, Steerenburg PA, Neijt JP, Gispen WH: Putative neurotropic factors in the protection of cisplatin-induced peripheral neuropathy in rats. Toxicol Appl Pharmacol 111: 514-522, 1991.
30. Treskes M, Nijtmans LG, Fichtinger Scepman AM, Van der Vijgh WJ: Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethylcarbamate. Biochem Pharmacol 43: 1013-1019, 1992.
31. Bodenner DL, Dedon PC, Keng PC, Borch RF: Effect of dithiocarbamate on cis-diamminedichloroplatinum (Il)-induced cytotoxicity, DNA cross-linking, and γ-glutamyl transpeptidase inhibition. Cancer Res 46: 2745-2750, 1986.
32. Treskes M, Van der Vijgh WJ: WR2721 as a modulator of cisplatin-and carboplatin induced side effects in comparison with other chemoprotective agents: a molecular approach. Cancer Chemother Pharmacol 33: 93-106, 1993.
33. Shimada H, Takahashi K, Funakoshi T, Kojima S: Protective effects of dithiocarbamates against toxicity of cis-diamminedichloroplatinum in mice. Biol Pharma Bull 16: 368-371, 1993.
34. Hidaka S, Tsuruoka M, Funakoshi T, Shimada H, Kiyozumi M, Kojima S: Protective effects of dithiocarbamates against renal toxicity of cis-diamminedichloroplatinum in rats. Ren Fail 16: 337-349, 1994.
35. Walker EM Jr, Fazekas May MA, Heard KW, Yee S, Montague D, Jones MM: Prevention of cisplatin-induced toxicity by selected dithiocarbamates. Ann Clin Lab Sci 24: 121-133, 1994.
36. Van der Vijgh WJF, Peters GJ: Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (ethyol): preclinical aspects. Semin Oncol 5: 2-7, 1994.
37. Mollman JE: Protection against cis-platin neurotoxicity in cultured dorsal root ganglion cell by WR-2721. Proc 7th Int Conf on Chemical Modifiers of Cancer Treatment 328, 1991.
38. Muller LJ, Moorer-Van Delfl CM, Treskes M, Vermorken JB, Van der Vijgh WJF, Boer HH: WR 2721 protects neurons of the snail Lymnacea stanalis from cisplatin-induced toxicity. Proc AACR 33: 557, 1992.
39. Tedeschi M, De Cesare A, Oriana S, Perego P, Silva A, Venturino P, Zunino F: The role of glutathione in combination with cisplatin in the treatment of ovarian cancer, Cancer Treat Rev 18: 253-259, 1991.
40. De Vries EG, Hamilton TC, Lind M, Dauplat J, Neijt JP, Ozols RF: Advanced ovarian cancer. Drug resistence, supportive care and dose intensity. Ann Oncol 4: S57-62, 1993.
41. Zunino F, Pratesi G, Micheloni, Cavalletti E, Sala F, Tofanetti O: Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact 70: 89-101, 1989.
42. Di Re F, Bohm S, Oriana S, Spatti GB, Zunino F: High dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol 4: 55-61, 1993.
43. Hamers FPT, Brakkee JH, Cavalletti E, Tedeschi M, Marmonti L, Pezzoni G, Neijt JP, Gispen WH: Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 53: 544-549, 1993.
44. Tredici G, Cavaletti G, Petruccioli MG, Fabbrica D, Tedeschi M, Venturino P: Low-dose glutathione administration in the prevention of cisplatin-induced peripheral neuropathy in rats. Neurotoxicol 15: 701-704, 1994.
45. Cavaletti G, Minoia C, Schieppati M, Tredici G: Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys 4: 771-776, 1994.
46. De Konig P, Brakkee JH, Gispen WH: Methods for producting a reproducible crush in the sciatic and tibial nerve of the rat and rapid and precise testing of return of sensory function. Beneficial effects of melanocortins. J Neurol Sci 74: 237-246, 1986.
47. Strand FL, Rose KJ, King JA, Segarra AC, Zuccarelli LA: ACTH modulation of nerve development and regeneration. Prog Neurobiol 33: 45-85, 1989.
48. Windenbank AJ, Smith AG, Russel JW: The effect of nerve growth factor, ciliary neurotrophic factor, and ACTH analogs on cisplatin neurotoxicity in vitro. Neurol 44: 488-494, 1994.
49. 4-9 analogue against the toxic effects of cisplatin and taxol on sensory neurons and glial cells in vitro. J Neurosci Res 39: 178-185, 1994.
50. Hamers FPT, Pette C, Bravenboer B, Vecht CJ, Neijt JP, Gispen WH: Cisplatin-induced neuropathy in mature rats: effects of the melanocortin-derived peptide ORG 2766. Cancer Chemother Pharmacol 32: 162-166, 1993.
51. Gerritsen Van der Hoop R, De Konig P, Boven E, Neijt JP, Jennekens FGI, Gispen WH: Efficacy of the neuropeptide ORG 2766 in the prevention and treatment of cisplatin induced neurotoxicity in rats. Eur J Cancer Clin Oncol 24: 637-642, 1988.
52. Mueller LJ, Gerritsen Van der Hoop R, Van Delft CMM, Gispen WH, Roubos EW: Morphological and electrophysiological study of the effects of cisplatin and ORG 2766 on rat spinal ganglion neurons. Cancer Res 50: 2437-2442, 1990.
53. (4-9) analog to affect cisplatin ototoxicity: an electrocochleographic study in guinea pigs. Eur Arch Otorhinolaryngol 251: 23-29, 1994.
54. Malgrange B, Delree P, Rigo JM, Baron H, Moonen G: Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. J Neurosci Methods 53: 111-122, 1994.
55. Gao W-Q, Dybdal N, Shinsky N, Murnane A, Schmelzer C, Siegel M, Keller G, Hefti F, Phillips HS, Winslow JW: Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 38: 30-37, 1995.
56. Konings PNM, Makkink WK, Van Delft AML, Ruigt GSF: Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro. Brain Res 640: 195-204, 1994.
57. Hayakawa K, Sobue G, Itoh T, Terunori M: Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro. Life Sci 7: 519-525, 1994.
58. Apfel SC, Arezzo JC, Lipson LA, Kessler JA: Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 31: 76-80, 1992.
59. Konings PN, Philipsen RL, Veeneman GH, Ruigt GS: Alpha-sialyl cholesterol increases lamin in schwann cell cultures and attenuates cytostatic drug-induced reduction of lamin. Brain Res 654: 118-128, 1994.
60. Whitaker-Azmitia PM, Raio M, Raio D, Borella A: A 5-HT3 receptor antagonist fails to prevent cisplatin-induced toxicity in immature rat spinal cord. Eur J Pharmacol 275: 139-143, 1995.
61. Chen KK, Rose CL: Nitrite and thiosulfate therapy in cyanide poisoning. JAMA 149: 113-119, 1952.
62. Howell SB, Taetle R: Effect of sodium thiosulfate on cis-dichlorodiammineplatinum (II) toxicity and antitumor activity in L1210 leukemia. Cancer Treat Rep 64: 611-616, 1980.
63. Iwamoto Y, Kawano T, Uozumi, Aoki K, Baba T: Two-route chemotherapy using high dose ip cisplatin and iv sodium thiosulfate, its antidote for peritoneally disseminated cancer in mice. Cancer Treat Rep 68: 1367-373, 1984.
64. Pfeile CE, Howell SB, Fclthousc RD, Woliver TBS, Andrews PA, Markman M, Murphy MP: High-dose cisplatin with sodium thoisulfate protection. J Clin Oncol 3: 237-244, 1985.
65. Iannotti N, Markman M, D'Acquisto R, Hakes T, Bajorin D, Kris M, Bosl G, Casper E, Reichman, Magill G, Budnick A: Phase I trial of escalating doses of intravenous (iv) cisplatin (c) with iv sodium thiosulfate (sts) renal protection. Proc ASCO 7: 55, 1988.
66. Gandara DR, Peres EA, Lawrence HJ, DeGregorio MW: Phase I trial of high dose cisplatin plus DDTC rescue: toxicity profile compared to patients receiving high dose cisplatin alone. Proc AACR 30: 241, 1989.
67. Berry JM, Jacobs C, Sikic B, Halsey J, Borch RF: Modification of cisplatin toxicity with diethyldithiocarbamate. J Clin Oncol 8: 1585-1590, 1990.
68. Paredes J, Hong WK, Felder TB, Felder TB, Dimery IW, Choksi AJ, Newman RA, Castcllanos AM, Robbins KT, McCarthy K, Atkinson N, Kramer AM, Hersh EM, Goepfert H: Prospective randomized trial of high-dose cisplatin and fluorouracil infusion with or without sodium diethyldithiocarbamate in recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 6: 955-962, 1988.
69. Gandara DR, Hoff JV, Reich SD, the MGI Investigators Group: Phase III evaluation of diethyldithiocarbamate as a chemoprotective agent against cisplatin induced toxicities. Proc ASCO 12: 388, 1993.
70. Scrip No 1714 May 1st, 1992.
71. Glover D, Glick J, Weiler C, Yuhas J, Kligerman MM: Phase I trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys 10: 1781-1784, 1984.
72. Kligerman M, Glover D, Turrisi AT, Norfleet AL, Yuhas JM, Coia LR, Simone C, Glick JH, Goodman RL: Toxicity of WR-2721 administered in single and multiple doses. Int J Radiat Oncol Biol Phys 10: 1773-1776, 1984.
73. Kemp GM, Glover DJ, Schein PS: The role of WR-2721 in the reduction of combined cisplatin and cyclophosphamide toxicity. Proc ASCO 9: 67, 1990.
74. Glick J, Kemp G, Rose P, Mitchell E, Reynolds R, Schleffer B, Capizzi R: A randomized trial of cyclophosphamide and cisplatin ± amifostine in the treatment of advanced epithelial ovarian cancer. ProcASCO 13: 1485, 1994.
75. Budd GT, Lorenzi V, Ganapathi R, Adelstein D, Pelley R, Olencki T, McLain D, Bukowski RM: Amifostine: potential for clinically useful cytoprotection. Support Care Cancer 2: 380-384, 1994.
76. Capizzi RL: Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (ethyol): clinical experience. Semin Oncol 21: 8-15, 1994.
77. Scrip No. 2035: 22, 20th June 1995.
78. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G: Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo controlled trial. J Clin Oncol 1: 26-32, 1995.
79. Smyth J, Bowman A, Perren T, Wilkinson P, Prescott R: Glutathione improves the therapeutic index of cisplatin and quality of life for patients with ovarian cancer Proc ASCO 14: 761, 1995.
80. Colombo N, Bini S, Miceli D, Bogliun G, Marzorati G, Cavaletti G, Parmigiani F, Venturino P, Tedeschi M, Frattola L, Buratti C, Mangioni C: Weekly cisplatin±glutathione in relapsed ovarian carcinoma. Int J Gynecol Cancer 5: 81-86, 1995.
81. Bogliun G, Marzorati L, Cavaletti G, Marzola M, Miceli MD, Cantù MG: Neurotoxicity of cisplatin±reduced glutathione in the first-line treatment of advanced ovarian cancer. Submitted for publication to the Int J Gynecol Cancer.
82. De Haes JCJM, Van Knippenberg FCE, Nejit JP: Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer 61: 1034-1038, 1990.
83. (4-9) analogue in patients with ovarian cancer. N Engl J Med 322: 89-94, 1990.
84. (4-9) analogue, for the prevention of neuropathy induced by cisplatin with or without vinca-alcaloids combination chemotherapy. Eur J Cancer 206: 1152, 1993.